JP2023515576A5 - - Google Patents

Info

Publication number
JP2023515576A5
JP2023515576A5 JP2022551290A JP2022551290A JP2023515576A5 JP 2023515576 A5 JP2023515576 A5 JP 2023515576A5 JP 2022551290 A JP2022551290 A JP 2022551290A JP 2022551290 A JP2022551290 A JP 2022551290A JP 2023515576 A5 JP2023515576 A5 JP 2023515576A5
Authority
JP
Japan
Prior art keywords
epilepsy
alkyl
group
hydrogen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022551290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515576A (ja
JP7699836B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019814 external-priority patent/WO2021173930A1/en
Publication of JP2023515576A publication Critical patent/JP2023515576A/ja
Publication of JP2023515576A5 publication Critical patent/JP2023515576A5/ja
Application granted granted Critical
Publication of JP7699836B2 publication Critical patent/JP7699836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551290A 2020-02-28 2021-02-26 Kcnt1阻害剤、および使用方法 Active JP7699836B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062982830P 2020-02-28 2020-02-28
US202062982838P 2020-02-28 2020-02-28
US202062982804P 2020-02-28 2020-02-28
US62/982,830 2020-02-28
US62/982,804 2020-02-28
US62/982,838 2020-02-28
PCT/US2021/019814 WO2021173930A1 (en) 2020-02-28 2021-02-26 Kcnt1 inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2023515576A JP2023515576A (ja) 2023-04-13
JP2023515576A5 true JP2023515576A5 (cg-RX-API-DMAC10.html) 2024-03-04
JP7699836B2 JP7699836B2 (ja) 2025-06-30

Family

ID=77492026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551290A Active JP7699836B2 (ja) 2020-02-28 2021-02-26 Kcnt1阻害剤、および使用方法

Country Status (11)

Country Link
US (2) US12583849B2 (cg-RX-API-DMAC10.html)
EP (2) EP4110317B1 (cg-RX-API-DMAC10.html)
JP (1) JP7699836B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230005813A (cg-RX-API-DMAC10.html)
CN (1) CN115443129A (cg-RX-API-DMAC10.html)
AU (2) AU2021227935B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022017191A2 (cg-RX-API-DMAC10.html)
CA (1) CA3169779A1 (cg-RX-API-DMAC10.html)
IL (2) IL295940B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022010625A (cg-RX-API-DMAC10.html)
WO (1) WO2021173930A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
CN120817941A (zh) * 2019-05-03 2025-10-21 普拉克西斯精密药物股份有限公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2026082925A1 (en) 2024-10-18 2026-04-23 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of their use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JP2005060255A (ja) 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US20080269241A1 (en) 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US8445686B2 (en) * 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2015150097A1 (en) 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
EP3275440B1 (en) 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
JPWO2017170826A1 (ja) 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−1受容体作用増強活性を有する化合物
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN120817941A (zh) * 2019-05-03 2025-10-21 普拉克西斯精密药物股份有限公司 Kcnt1抑制剂和使用方法
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
EP4446314A3 (en) 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
KR20230005168A (ko) 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CN116075297A (zh) 2020-07-06 2023-05-05 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240043415A1 (en) 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4536644A4 (en) 2022-06-08 2026-05-20 Praxis Prec Medicines Inc KCNT1 INHIBITORS COMPRISING AN ISOXAZOLE OR OXADIAZOLE NUCLEUS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2022530989A5 (cg-RX-API-DMAC10.html)
JP2023518838A5 (cg-RX-API-DMAC10.html)
JP2023532985A5 (cg-RX-API-DMAC10.html)
KR102943760B1 (ko) 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
TW202200552A (zh) 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑
JP2014524472A5 (cg-RX-API-DMAC10.html)
JP2004107358A (ja) 新規置換イミダゾール化合物
JP2022531388A5 (cg-RX-API-DMAC10.html)
JP2022550640A5 (cg-RX-API-DMAC10.html)
EP3013815B1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
JP2005514398A5 (cg-RX-API-DMAC10.html)
JP2021105002A5 (cg-RX-API-DMAC10.html)
JP2008524328A5 (cg-RX-API-DMAC10.html)
JPWO2020017587A5 (cg-RX-API-DMAC10.html)
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
JP2010505794A5 (cg-RX-API-DMAC10.html)
JP6793657B2 (ja) 置換三環式ヘテロ環式化合物
JP2006508107A5 (cg-RX-API-DMAC10.html)
JP2011515482A5 (cg-RX-API-DMAC10.html)
JP2011503193A5 (cg-RX-API-DMAC10.html)
RU2015101532A (ru) Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5
JP2011079828A5 (cg-RX-API-DMAC10.html)
JP2008513413A5 (cg-RX-API-DMAC10.html)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений